0000950170-24-072572.txt : 20240612 0000950170-24-072572.hdr.sgml : 20240612 20240612173233 ACCESSION NUMBER: 0000950170-24-072572 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240612 DATE AS OF CHANGE: 20240612 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 241039432 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: ROBIN SHERRINGTON CENTRAL INDEX KEY: 0001619962 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: C/O XENON PHARMACEUTICALS INC. STREET 2: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G4W8 144 1 primary_doc.xml 144 0001619962 XXXXXXXX LIVE 0001582313 Xenon Pharmaceuticals Inc. 001-36687 200-3650 Gilmore Way Burnaby A1 V5G 4W8 (604)-484-3300 ROBIN SHERRINGTON Officer (non-Section 16) Common Shares Morgan Stanley Wealth Management Canada Inc.

Suite 1500, 600 - 3 Avenue SW Calgary Z4 T2P 0G5

60000 2301600 75468883 06/12/2024 NASDAQ Stock Option 12/18/2015 Equity Incentive Grant Issuer N 15000 06/12/2024 See remarks Stock Option 03/11/2016 Equity Incentive Grant Issuer N 20000 06/12/2024 See remarks Stock Option 03/13/2017 Equity Incentive Grant Issuer N 27500 06/12/2024 See remarks Stock Option 10/23/2017 Equity Incentive Grant Issuer N 11000 06/12/2024 See remarks Y During the 90-day period following the filing of this Form 144, the reporting person anticipates selling up to 60,000 common shares resulting from the net exercise of the listed stock options. 06/12/2024 /s/ Robin Sherrington